Suppr超能文献

纤溶酶原激活物抑制剂-1中玻连蛋白结合域的定位

Localization of vitronectin binding domain in plasminogen activator inhibitor-1.

作者信息

Lawrence D A, Berkenpas M B, Palaniappan S, Ginsburg D

机构信息

Department of Internal Medicine, University of Michigan, Ann Arbor 48109-0650.

出版信息

J Biol Chem. 1994 May 27;269(21):15223-8.

PMID:7515053
Abstract

Plasminogen activator inhibitor type 1 (PAI-1) is the rapid physiologic inhibitor of tissue-type plasminogen activator and urokinase-type plasminogen activator (uPA). In plasma and the extracellular matrix, PAI-1 is associated with the adhesive glycoprotein vitronectin. In order to characterize the PAI-1 structural domain responsible for binding to vitronectin, the segment of the PAI-1 cDNA encoding amino acids 13-147 (nucleotides 248-650) was randomly mutagenized and subcloned into a bacterial expression vector containing the mature PAI-1 coding sequence. Recombinant PAI-1 mutants were expressed in Escherichia coli and bacterial lysates assayed in duplicate for uPA inhibitory activity and vitronectin binding. Of 190 clones screened, six consistently demonstrated decreased vitronectin binding relative to uPA inhibitory activity. DNA sequence analysis of four of these clones identified 10 unique missense mutations, all located between base pairs 298 and 641, with each clone containing between one and four substitutions. Each substitution was expressed independently by site-directed mutagenesis and again analyzed for uPA inhibitory activity and vitronectin binding. Five point mutations that selectively disrupt vitronectin binding were identified. All 5 residues are located on the exterior of the PAI-1 structure. These findings appear to define a complex binding surface that bridges alpha-helices C and E to beta-strand 1A and includes amino acids 55, 109, 110, 116, and 123. These results suggest that vitronectin binding may stabilize the active conformation of PAI-1 by restricting the movement of beta-sheet A and thereby preventing insertion of the reactive center loop.

摘要

纤溶酶原激活物抑制剂1型(PAI-1)是组织型纤溶酶原激活物和尿激酶型纤溶酶原激活物(uPA)的快速生理性抑制剂。在血浆和细胞外基质中,PAI-1与黏附糖蛋白玻连蛋白相关联。为了鉴定负责与玻连蛋白结合的PAI-1结构域,对编码氨基酸13 - 147(核苷酸248 - 650)的PAI-1 cDNA片段进行随机诱变,并亚克隆到包含成熟PAI-1编码序列的细菌表达载体中。重组PAI-1突变体在大肠杆菌中表达,细菌裂解物一式两份测定uPA抑制活性和玻连蛋白结合情况。在筛选的190个克隆中,有6个相对于uPA抑制活性,始终表现出玻连蛋白结合减少。对其中4个克隆进行DNA序列分析,鉴定出10个独特的错义突变,均位于碱基对298和641之间,每个克隆包含1至4个取代。通过定点诱变独立表达每个取代,并再次分析uPA抑制活性和玻连蛋白结合情况。鉴定出5个选择性破坏玻连蛋白结合的点突变。所有5个残基都位于PAI-1结构的外部。这些发现似乎定义了一个复杂的结合表面,该表面将α螺旋C和E连接到β链1A,并包括氨基酸55、109、110、116和123。这些结果表明,玻连蛋白结合可能通过限制β折叠A的运动,从而防止反应中心环的插入,来稳定PAI-1的活性构象。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验